Your browser doesn't support javascript.
loading
Rapid depletion of "catch-and-release" anti-ASGR1 antibody in vivo.
Devanaboyina, Siva Charan; Li, Peng; LaGory, Edward L; Poon-Andersen, Carrie; Cook, Kevin D; Soto, Marcus; Wang, Zhe; Dang, Khue; Uyeda, Craig; Case, Ryan B; Thomas, Veena A; Primack, Ronya; Ponce, Manuel; Di, Mei; Ouyang, Brian; Kaner, Joelle; Lam, Sheung Kwan; Mostafavi, Mina.
Afiliação
  • Devanaboyina SC; Department of Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
  • Li P; Department of Biologics, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
  • LaGory EL; Department of Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
  • Poon-Andersen C; Department of Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
  • Cook KD; Department of Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
  • Soto M; Department of Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc, Thousand Oaks, CA, USA.
  • Wang Z; Department of Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
  • Dang K; Department of Biologics, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
  • Uyeda C; Department of Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
  • Case RB; Department of Lead Discovery and Characterization, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
  • Thomas VA; Department of Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
  • Primack R; Department of Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc, Thousand Oaks, CA, USA.
  • Ponce M; Department of Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc, Thousand Oaks, CA, USA.
  • Di M; Department of Cardiometabolic disorders, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
  • Ouyang B; Department of Biologics, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
  • Kaner J; Department of Biologics, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
  • Lam SK; Department of Biologics, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
  • Mostafavi M; Department of Biologics, Amgen Research, Amgen Inc, South San Francisco, CA, USA.
MAbs ; 16(1): 2383013, 2024.
Article em En | MEDLINE | ID: mdl-39051531
ABSTRACT
Targeting antigens with antibodies exhibiting pH/Ca2+-dependent binding against an antigen is an attractive strategy to mitigate target-mediated disposition and antigen buffering. Studies have reported improved serum exposure of antibodies exhibiting pH/Ca2+-binding against membrane-bound receptors. Asialoglycoprotein receptor 1 (ASGR1) is a membrane-bound receptor primarily localized in hepatocytes. With a high expression level of approximately one million receptors per cell, high turnover, and rapid recycling, targeting this receptor with a conventional antibody is a challenge. In this study, we identified an antibody exhibiting pH/Ca2+-dependent binding to ASGR1 and generated antibody variants with increased binding to neonatal crystallizable fragment receptor (FcRn). Serum exposures of the generated anti-ASGR1 antibodies were analyzed in transgenic mice expressing human FcRn. Contrary to published reports of increased serum exposure of pH/Ca2+-dependent antibodies, the pH/Ca2+-dependent anti-ASGR1 antibody had rapid serum clearance in comparison to a conventional anti-ASGR1 antibody. We conducted sub-cellular trafficking studies of the anti-ASGR1 antibodies along with receptor quantification analysis for mechanistic understanding of the rapid serum clearance of pH/Ca2+-dependent anti-ASGR1 antibody. The findings from our study provide valuable insights in identifying the antigens, especially membrane bound, that may benefit from targeting with pH/Ca2+-dependent antibodies to obtain increased serum exposure.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Camundongos Transgênicos / Receptores Fc / Antígenos de Histocompatibilidade Classe I / Receptor de Asialoglicoproteína Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Camundongos Transgênicos / Receptores Fc / Antígenos de Histocompatibilidade Classe I / Receptor de Asialoglicoproteína Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article